242 related articles for article (PubMed ID: 38253184)
1. Comparative efficacy, tolerability and acceptability of donanemab, lecanemab, aducanumab and lithium on cognitive function in mild cognitive impairment and Alzheimer's disease: A systematic review and network meta-analysis.
Terao I; Kodama W
Ageing Res Rev; 2024 Feb; 94():102203. PubMed ID: 38253184
[TBL] [Abstract][Full Text] [Related]
2. Comparative Efficacy, Tolerability, and Acceptability of Donanemab, Lecanemab, Aducanumab, Melatonin, and Aerobic Exercise for a Short Time on Cognitive Function in Mild Cognitive Impairment and Mild Alzheimer's Disease: A Systematic Review and Network Meta-Analysis.
Terao I; Kodama W
J Alzheimers Dis; 2024; 98(3):825-835. PubMed ID: 38461503
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy of lithium and aducanumab for cognitive decline in patients with mild cognitive impairment or Alzheimer's disease: A systematic review and network meta-analysis.
Terao I; Honyashiki M; Inoue T
Ageing Res Rev; 2022 Nov; 81():101709. PubMed ID: 35961514
[TBL] [Abstract][Full Text] [Related]
4. Comparative Efficacy and Safety of Monoclonal Antibodies for Cognitive Decline in Patients with Alzheimer's Disease: A Systematic Review and Network Meta-Analysis.
Qiao Y; Gu J; Yu M; Chi Y; Ma Y
CNS Drugs; 2024 Mar; 38(3):169-192. PubMed ID: 38429615
[TBL] [Abstract][Full Text] [Related]
5. Clinically Important Benefits and Harms of Monoclonal Antibodies Targeting Amyloid for the Treatment of Alzheimer Disease: A Systematic Review and Meta-Analysis.
Ebell MH; Barry HC; Baduni K; Grasso G
Ann Fam Med; 2024; 22(1):50-62. PubMed ID: 38253509
[TBL] [Abstract][Full Text] [Related]
6. Lecanemab in Early Alzheimer's Disease.
van Dyck CH; Swanson CJ; Aisen P; Bateman RJ; Chen C; Gee M; Kanekiyo M; Li D; Reyderman L; Cohen S; Froelich L; Katayama S; Sabbagh M; Vellas B; Watson D; Dhadda S; Irizarry M; Kramer LD; Iwatsubo T
N Engl J Med; 2023 Jan; 388(1):9-21. PubMed ID: 36449413
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US.
Ross EL; Weinberg MS; Arnold SE
JAMA Neurol; 2022 May; 79(5):478-487. PubMed ID: 35344024
[TBL] [Abstract][Full Text] [Related]
8. Potential impact of unblinding on observed treatment effects in Alzheimer's disease trials.
Wolters FJ; Labrecque JA
Alzheimers Dement; 2024 Apr; 20(4):3119-3125. PubMed ID: 38380503
[TBL] [Abstract][Full Text] [Related]
9. Profiling lecanemab as a treatment option for Alzheimer's disease.
Schiller ER; Silverglate BD; Grossberg GT
Expert Rev Neurother; 2024 May; 24(5):433-441. PubMed ID: 38566584
[TBL] [Abstract][Full Text] [Related]
10. Pharmacologic and Nutritional Interventions for Early Alzheimer's Disease: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Zeng B; Tang C; Wang J; Yang Q; Ren Q; Liu X
J Alzheimers Dis; 2024; 99(4):1173-1186. PubMed ID: 38759015
[TBL] [Abstract][Full Text] [Related]
11. Donanemab: Not two without a third.
Kurkinen M
Adv Clin Exp Med; 2023 Oct; 32(10):1085-1087. PubMed ID: 37831471
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic evaluation of donanemab for the treatment of Alzheimer's.
Song T; Wang Y; Silverglate BD; Grossberg GT
Expert Opin Drug Metab Toxicol; 2024 Jun; 20(6):411-417. PubMed ID: 38758223
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of anti-amyloid-β monoclonal antibodies in current Alzheimer's disease phase III clinical trials: A systematic review and interactive web app-based meta-analysis.
Jeremic D; Navarro-López JD; Jiménez-Díaz L
Ageing Res Rev; 2023 Sep; 90():102012. PubMed ID: 37423541
[TBL] [Abstract][Full Text] [Related]
14. Novel anti-amyloid-beta (Aβ) monoclonal antibody lecanemab for Alzheimer's disease: A systematic review.
Chowdhury S; Chowdhury NS
Int J Immunopathol Pharmacol; 2023; 37():3946320231209839. PubMed ID: 37902139
[TBL] [Abstract][Full Text] [Related]
15. Donanemab in Early Alzheimer's Disease.
Mintun MA; Lo AC; Duggan Evans C; Wessels AM; Ardayfio PA; Andersen SW; Shcherbinin S; Sparks J; Sims JR; Brys M; Apostolova LG; Salloway SP; Skovronsky DM
N Engl J Med; 2021 May; 384(18):1691-1704. PubMed ID: 33720637
[TBL] [Abstract][Full Text] [Related]
16. Bayesian meta-analysis of phase 3 results of aducanumab, lecanemab, donanemab, and high-dose gantenerumab in prodromal and mild Alzheimer's disease.
Teipel SJ; Temp AGM; Lutz MW
Alzheimers Dement (N Y); 2024; 10(1):e12454. PubMed ID: 38389855
[TBL] [Abstract][Full Text] [Related]
17. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
Sims JR; Zimmer JA; Evans CD; Lu M; Ardayfio P; Sparks J; Wessels AM; Shcherbinin S; Wang H; Monkul Nery ES; Collins EC; Solomon P; Salloway S; Apostolova LG; Hansson O; Ritchie C; Brooks DA; Mintun M; Skovronsky DM;
JAMA; 2023 Aug; 330(6):512-527. PubMed ID: 37459141
[TBL] [Abstract][Full Text] [Related]
18. Donanemab, another anti-Alzheimer's drug with risk and uncertain benefit.
Høilund-Carlsen PF; Alavi A; Barrio JR; Castellani RJ; Costa T; Herrup K; Kepp KP; Neve RL; Perry G; Revheim ME; Robakis NK; Sensi SL; Vissel B
Ageing Res Rev; 2024 Jun; ():102348. PubMed ID: 38830549
[TBL] [Abstract][Full Text] [Related]
19. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.
Swanson CJ; Zhang Y; Dhadda S; Wang J; Kaplow J; Lai RYK; Lannfelt L; Bradley H; Rabe M; Koyama A; Reyderman L; Berry DA; Berry S; Gordon R; Kramer LD; Cummings JL
Alzheimers Res Ther; 2021 Apr; 13(1):80. PubMed ID: 33865446
[TBL] [Abstract][Full Text] [Related]
20. How promising are the latest monoclonal antibodies targeting amyloid-β for the treatment of early Alzheimer's disease?
Beveridge J; Kaniecki E; Naidu A; Silverglate BD; Grossberg G
Expert Opin Emerg Drugs; 2024 Mar; 29(1):35-43. PubMed ID: 38193477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]